Novel approaches: Gene editing therapies like NTLA-2001 from Intellia Therapeutics offer ... may lead to wider adoption across the ATTR-CM patient population. 3. Combination therapy potential ...

Novel approaches: Gene editing therapies like NTLA-2001 from Intellia Therapeutics offer the promise of ... may lead to wider adoption across the ATTR-CM patient population. 3. Combination therapy ...

Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this Journal Club, Minoli Perera reflects on a 2005 sequencing study by Cohen et al., who discovered two common loss-of-function mutations with large effects on plasma cholesterol levels thanks ...

Forbes does not accept payment for placement on lists.

After hours: March 21 at 7:48:22 PM EDT ...